A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, ...
Top stock picks for capital appreciation and outperformance, with a focus on profits, dividends, and long-term viability. Click for more on Capital Appreciation.
Q4 2024 Earnings Call Transcript February 6, 2025 Bristol-Myers Squibb Company beats earnings expectations. Reported EPS is ...
In a report released today, Srikripa Devarakonda from Truist Financial reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report).
Citi analyst Geoff Meacham maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target of $65.00. The ...
Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...
Bristol Myers Squibb is ending work on a handful of assets, including an immunology medication that was in two Phase 3 trials ...
The return of President Donald Trump to the White House has negatively impacted ESG initiatives, particularly in areas related to investment strateg ...
Bristol Myers Squibb reported strong fourth-quarter earnings but its outlook for 2025 failed to meet expectations.
The company also issued a 2025 guidance that fell short of expectations, as some of the company’s older drugs face ...